In continuation of our earlier intimation dated October 22, 2026 please find attached the Investor Presentation to be made during the said Analyst / Institutional Investors meet

October 27, 2026 BSE Limited National Stock Exchange of India Limited P J Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543904 Symbol: MANKIND Dear Sir/ Madam, Sub.: Investor Presentation Ref.: Regulation 30 & 51 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) Pursuant to Regulation 30 & 51 of the Listing Regulations and in continuation of our earlier intimation dated October 22, 2026 under subject “Intimation of Schedule of Analyst / Institutional Investors’ Meet”, please find attached Investor Presentation to be made during the said Analyst / Institutional Investors’ Meet. You are requested to take the above information on record and disseminate the same on your respective websites. The above information is also available on the website of the Company at www.mankindpharma.com. Thanking you Yours Faithfully, For Mankind Pharma Limited Hitesh Kumar Jain Company Secretary & Compliance Officer Encl.: A/a A NA LYST / INVESTOR MEET Mankind Pharma October 2026 Our DNA | Evolution 1995 – 2026 1995–2002 2002–2005 2007 2020–2022 2023 2024–2026 FOUNDATION METROS & CHRONIC BRAND MANKIND SPECIALTY PUBLIC LISTING COMPLEX & GLOBAL • Started from small • Metros and Tier-1 • Entered Consumer • Specialty divisions: • Listed on NSE & BSE • BSV acquisition towns and GPs cities Healthcare cardio, diabetes, • In-licensing/ Products • In-licensing/ Products • GPs to CPs • Expansion into South • Manforce, Prega respiratory, CNS acquired– Biocon acquired: • Gradual launch, state India News • Super-specialty: AstraZeneca by state • Stepped into chronic Panacea–onco& Novartis (2004) transplant Roche • Chronic became >30% • In-licensing/ Products acquired– Novartis 1995 2001 2007 2018 FY23 FY26 REVENUE TRAJECTORY ₹5+ Cr ₹50+ Cr ₹500+ Cr ₹5k+ Cr ₹8.7k+ Cr ₹14.2k+ Cr Mankind Today | FY26 at a glance Youngest ₹14,278 Cr 18.1% company in the IPM top 5 FY26 revenue Revenue CAGR, FY21–26 MARKET LEADERSHIP #1 #4 4 22 Prescription rank for 9 IPM rank by value Consumer brands ranked Brand families > ₹100 Cr years #1 COMMERCIAL REACH 5 lakh+ 18,500+ 17,600+ 84% Doctors covered Field force Stockists nationwide Prescriber penetration Source: IQVIA MAT Mar’26. 3 R&D | From Fixed-Dose Combination to novel molecules R&D JOURNEY 2012 2018–19 2024 FY26 First R&D centre First in India Biologics platforms Towards innovation IMT Manesar, Haryana Dydrogesterone developed in- BSV – recombinants Own NCE house (Dydroboon) GPR-119 in Phase II JAK inhibitor in Phase I TODAY · FY26 7 740+ 58 R&D centres Scientists US ANDAs approved Manufacturing | From third-party to ~75% in-house MANUFACTURING EVOLUTION 1995–2001 Build-out Global quality Today · FY26 32 manufacturing Asset-light start 7 plants ~75% in-house facilities 100% third-party manufacturing in Built across USFDA-approved Of manufacturing the first 6–7 years Himachal Pradesh, EU GMP-certified Mankind-owned or controlled plants Sikkim, Rajasthan and more; 5,000+ manufacturing staff KEY HIGHLIGHTS 2023 FY27–28 Backward integration Complex biologics Udaipur Facility Vadodara biologics plant under way (EU GMP Certified) India’s 1st fully integrated Dydrogesteroneplant FY24 – FY26 | Transformation KEY INITIATIVES PORTFOLIO Leadership & Re-energised Doctor BSV ACQUISITION · FY25 Technology talent field force engagement Development and acquisition New KRA & incentive Optimisedengagement Extensive use in the field • High-entry barrier portfolio framework strategy& Medico Marketing • Women’s health, fertility & critical care • Biological R&D platforms GROWTH REVIVAL Volume growth (−0.6%) → +6.2% Outperforming IPM 6.2% vs 5.2% Volume growth vs IPM, Q2 FY27 IN-LICENSING/BRAND ACQUISITION · FY24–26 FY24 Q2 FY27 IPM Mankind Growth Value Volume Value Volume Productivity2 ANNUAL AstraZeneca Novartis FY24 7.6% 0.7% 8.5% -0.6% 6.5 FY25 8.0% 1.4% 7.5% 0.5% 6.5 FY26 9.9% 2.7% 8.2% 2.3% 7.2 Rivotril QUARTERLY Q1 FY27 13.0%1 4.7% 12.7% 4.7% 7.3 Takeda Roche Q2 FY27 14.2%1 5.2% 15.7% 6.2% 7.4 1. Ex-Tirzepatide(reported: Q1 FY27 13.5%, Q2 FY27 14.7%) 2. ₹ lakh per MR per month on TTM. Source: IQVIA; company data. Green = Mankind ahead of IPM. 6 OUTLOOK AHEAD | Outperform IPM EIGHT PILLARS OF GROWTH PILLAR 1 PILLAR 5 More brands above ₹50 / Chronic & Specialty Chronic share ~39% → ~50% Good to Great Brands ₹100 / ₹200 Cr • Cardio • GPDivision PILLAR 2 PILLAR 6 • Gastro • Dental New Divisions • Cosmetology Consumer Healthcare Transform • Geriatric PILLAR 3 PILLAR 7 Hospital Business Share of sales ~1.7% → ~5% BSV Scale branded specialty PILLAR 4 PILLAR 8 Break into the top 3 rank in ACTx; 10 Focus States Innovative Bets each state deleverage, then reinvest Capital Allocation Pillar 1 | Chronic & Specialty CHRONIC SHARE OF SALES From GPs -> CPs -> Super- Specialists HOW WE STARTED WHAT WE ADDED Cold & cough + Inhalers Combihale+ Symbicort–44% YoY, 3x IPM Oral anti-diabetic + Insulin Nobeglar–40% YoY growth FY04 FY18 FY26 FY30E Hypertension + Crenzlo (Inclisiran) 1 lac value #1 Rx brand in its category MARKET SHARE IN IPM (%) Cardiac Anti-diabetic OUTLOOK · PATH TO ~50% CHRONIC 5.5% 3.9% NewSpecialty New Products Good to great 4.5% divisions brands Build insulinand Scale more 3.2% Chronic inhaler franchises ₹50 Cr FY20 FY21 FY22 FY23 FY24 FY25 FY26 Semi-chronic ₹100 Cr ₹ 200 Cr Source: IQVIA MAT Mar’26 8 New Launches | Recent wins and the next wave SUCCESSFUL RECENT LAUNCHES Vonalong Nurokind HS PFS AdvaUD DynaDuo Vonoprazan MecobalaminPre-filled syringe Nor-UrsodeoxycholicAcid Empagliflozin+ Linagliptin IQVIA RANK MARKET SHARE IQVIA RANK MARKET SHARE IQVIA RANK MARKET SHARE IQVIA RANK MARKET SHARE #1 12% #2 12% #2 36% #4 5% UPCOMING BIG LAUNCHES 01 02 03 04 05 Resmetirom Insulin Aspart & Perfluoro-hexyloctane Latanoprostene bunod Ensifentrine Degludec NASH –fatty liver disease Diabetes –insulin franchise Dry eye disease Glaucoma COPD Source: IQVIA MAT Sep’26, Period: H1 FY27 9 Pillar 5 | Big Brands Getting Bigger BRAND FAMILIES BY SIZE ₹500 CR+ BRANDS (FY26) Sales band FY21 FY26 Added CAGR FY21–26 Telmikind ₹783 Cr FY26 growth > ₹500 Cr 0 3 +3 14.4% Nurokind ₹667 Cr FY26 growth Manforce ₹647 Cr > ₹200 Cr 7 13 +6 12.8% FY26 growth NEW ₹50 CR+ BRANDS IN FY26 > ₹100 Cr 15 22 +7 12.3% Lactare D3 Must Statpure > ₹50 Cr 36 54 +18 11.2% Mahaflox Ossopan Source: IQVIA MAT Mar’26, 10 Pillar 6 | Consumer Healthcare – From Sexual Wellness to Consumer Wellness WHAT WE HAVE BUILT OUTLOOK · NEXT PHASE OF GROWTH 1 Leader in sexual wellness Scale consumer healthcare #1 Manforce Condoms –28% share; strengthened flavoured range in general trade led by consumer wellness and new-age channels #1 Unwanted Emergency contraceptives –68% share Modern trade, e-com & quick-commerce 2 Owned pregnancy care Accelerate presence in new-age channels #1 Prega News Pregnancy test kits –83% share; extended into Ova News Premium & unflavoured condoms 3 Moved into consumer wellness Scale Epic ThinX; premiumise Manforce #2 Gas-O-Fast Antacid powder –11% share; Jeera variant widened appeal New wellness categories #1 Acne Star Medicated anti-acne –33% share; plus Health OK, Nimulid Scale Ova News, Nimulid, Health OK ₹879 Cr 4 4% → 8% → 14% Rx → OTx → OTC FY26 revenue Brands ranked #1 in their categories E-com share, FY25 →FY26→ Q2 FY27 Switch proven Rx brands to consumer channels Source: IQVIA Retail MAT Mar’26. 11 Pillar 7 | BSV – High-Barrier Specialty #1 #1 / #2 ~37K ~88% Gynaecology rank in India* In 9 key brand families Gynaecologists covered IVF centre coverage HIGH-BARRIER BRANDS & PLATFORMS FUTURE OUTLOOK Anti-D (recombinant) • Focus on high revenue growth First novel biologic from India; 100% market share in India • Deeper penetration in Anti-D, infertility and bitesportfolio • Good-to-great brands like Octaplex and Histoglob Humog (high-purity HMG) • Geographical expansionof key products in emerging markets Rank # [Showing first 8,000 characters — download PDF for full document]